FDA Approves First Treatment for Rare Barth Syndrome

1 min read
Source: fda.gov
FDA Approves First Treatment for Rare Barth Syndrome
Photo: fda.gov
TL;DR Summary

The FDA has granted accelerated approval to Forzinity (elamipretide) as the first treatment for Barth syndrome, a rare and serious mitochondrial disease, based on improvements in muscle strength that are likely to benefit patients, with further studies required to confirm these benefits.

Share this article

Reading Insights

Total Reads

0

Unique Readers

0

Time Saved

2 min

vs 3 min read

Condensed

90%

44242 words

Want the full story? Read the original article

Read on fda.gov